Down-regulation of Na+ transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia  by Andrade, Lúcia et al.
Kidney International, Vol. 65 (2004), pp. 175–183
Down-regulation of Na+ transporters and AQP2 is responsible
for acyclovir-induced polyuria and hypophosphatemia
LU´CIA ANDRADE, NANCY A. REBOUC¸AS, and ANTONIO CARLOS SEGURO
Department of Nephrology, Laboratory of Basic Research, University of Sa˜o Paulo School of Medicine, Sa˜o Paulo, Brazil;
Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sa˜o Paulo, Sa˜o Paulo, Brazil; and
Intensive Care Unit, Emı´lio Ribas Institute of Infectology, Sa˜o Paulo, Brazil
Down-regulation of Na+ transporters and AQP2 is responsible
for acyclovir-induced polyuria and hypophosphatemia.
Background. Acyclovir (ACY) is a useful therapeutic agent
for the systemic treatment of herpes virus infection. An increase
in urinary phosphate excretion and polyuria has been described.
The objective of this study was to analyze the exact mechanism
of the urinary-concentrating dysfunction and the increase in
phosphaturia associated with ACY.
Methods. We first analyzed 7 (adult and pediatric) non-AIDS
cases of encephalitis receiving 15 mg/kg bw/d of intravenous
ACY. Fractional phosphate and sodium excretion, urinary
potassium volume, and plasma phosphate concentrations were
analyzed. Additional studies in rats treated with intraperi-
toneal ACY (100 mg/kg bw) were also conducted. Ani-
mals were maintained in metabolic cages and 24-hour urine
samples were collected to measure volume, osmolality, and
sodium/potassium/phosphate excretion. Treated rats were also
evaluated after 24 hours and 48 hours of water deprivation.
Northern hybridization and semiquantitative immunoblotting
were performed to evaluate (in both control and treated
animals) expression of the cotransporters Na-Pi type IIa (Na-Pi-
IIa) and Na-K-2Cl (NKCC2). Semiquantitative immunoblot-
ting was carried out in the kidneys of ACY rats and control rats
in order to analyze aquaporin 2 (AQP2) protein expression.
Results. Patients started on ACY developed polyuria and
hyperphosphatemia after 48 hours. In rats, ACY-induced hy-
perphosphaturia and hypophosphatemia were accompanied by
increased excretion of sodium, potassium, and magnesium,
increased urine output, lower urinary osmolality, and a par-
tial urinary concentrating defect. Concurrent downregulation
of Na-Pi-IIa and NKCC2 expression was observed. There was
also a decrease in medullar expression of the AQP2 collecting
duct water channel.
Conclusion. Downregulation of Na-Pi-IIa appears to play
a crucial role in the downregulation of ACY-induced
hyperphosphaturia. The accompanying polyuria and urinary-
concentrating defect can in part be explained by the downreg-
ulation of NKCC2 and AQP2.
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Intravenous acyclovir (ACY) is the drug of choice
for treatment of herpes virus simplex encephalitis
and varicella-zoster infection of immunocompromised
hosts [1]. Acyclovir (9-[(2-hydroxy-ethoxy)methyl]-9H-
guanine) is an acyclic guanine nucleoside analog that
lacks a 3′-hydroxyl on the side chain. It inhibits viral DNA
synthesis and is selectively activated in cells infected
with herpes viruses that code for appropriate thymidine
kinases [2]. The principal dose-limiting toxic effect of
intravenous ACY is renal insufficiency. ACY is rapidly
excreted in the urine (being both filtered and secreted)
and has a relatively low solubility [3]. ACY-induced crys-
talluria has been described as a cause of renal dysfunction
[4, 5].
It has been observed that ACY can induce polyuria and
urine-concentrating dysfunction, even in the absence of
renal insufficiency. In an isolated microperfusion tubule
and inulin clearance study in rats, Campos et al [6] have
shown that ACY produces resistance to vasopressin in
the inner medullary collecting duct and tubular defects in
the thick ascending limb of Henle and proximal tubule.
Through renal brush border membrane vesicle, Monteiro
et al [7] have shown that, because phosphate reabsorp-
tion in the kidney occurs predominantly in the proximal
tubule fluid through Na-Pi cotransport, ACY can also
induce hyperphosphaturia by decreasing Na-dependent
phosphate uptake.
The objective of the present study was to analyze the
exact mechanism of the urinary- concentrating dysfunc-
tion associated with ACY-induced polyuria. We tested the
hypothesis that reduced expression of the encoding mem-
brane renal transporter genes might form the molecular
basis for the polyuria and hyperphosphaturia observed in
ACY-treated animals.
In the present study, we examined whether pa-
tients to whom intravenous ACY is administered devel-
oped polyuria and hyperphosphaturia. We also studied
ACY-treated rats maintained in metabolic cages allowing
quantitative and qualitative urine collections and mea-
surements of water intake, food intake, and body weight
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(bw). All of the animals studied developed polyuria
and hyperphosphaturia. Hypophosphatemia was also
observed. We examined the hypothesis that there exists a
correlation between the dramatic increase in both urinary
phosphate excretion and hypophosphatemia encoun-
tered in metabolic cage studies and the changes in the ex-
pression of the proximal tubule Na-Pi-IIa cotransporter
mRNA and protein abundance. We further examined
changes in the expression of NKCC2 mRNA and pro-
tein abundance in order to determine if they correlated
with the polyuria, a finding which would validate pre-
vious studies involving water-free inulin clearance [6]. In
addition, the relationship between urinary-concentration
defects and reduction of AQP2 protein expression was
also studied, as well as the urine-concentrating ability of
ACY-treated rats after 24 hours and 48 hours of water de-
privation. Finally, to determine whether, as hypothesized,
downregulation of Na-Pi-IIa transporter is specific—or
if other membrane proximal tubule transporters can be
affected—we measured the urinary excretion of glucose
in these animals.
METHODS
ACY-treated patients
We analyzed 7 (adult and pediatric) non-AIDS cases of
encephalitis admitted to the intensive care unit. These pa-
tients began receiving only intravenous ACY (15 mg/kg
bw/day). Polyuria and hyperphosphatemia developed
48 hours after treatment began. Urinary volume (mL/kg
bw/h), plasma phosphate concentration (mg/dL), and
fractional excretions of phosphate (FEP), of sodium
(FENa), and of potassium (FEK) were analyzed. No
diuretics, vasoactive drugs, or corticosteroids were
administered.
ACY-treated rats
Study design. Male Wistar rats weighing 150 to 250 g
were used in this study. The animals were separated
into 3 sets of 2 groups each. Each set consisted of one
control group and one study group. In the first series of
experiments, 14 ACY-treated rats and 14 control rats
were housed in metabolic cages for up to 17 days to ex-
amine phosphorus, sodium, potassium, magnesium, and
calcium concentrations in plasma and urine. Based on
these results, we chose day 8 of ACY treatment to be the
benchmark for subsequent series. In the second series,
we evaluated the effect of ACY on urine-concentrating
ability. In the third series, we examined whether the
ACY-induced renal defects observed are related to
changes in sodium transporters (Na-Pi-IIa, NKCC2) and
in AQP2 expression.
Metabolic cage studies. The rats were housed one per
cage, maintained on a 12-hour light/dark cycle and had
free access to drinking water and standard rat chow. The
animals were acclimated to the housing conditions for a
few days before the experimental procedures. Baseline
urine samples were collected over a period of 24 hours
before the treatment (pre-ACY) by placing the animals
in individual cages. On day 1, subject rats were injected
intraperitoneally with 100 mg/kg bw ACY in saline solu-
tion with a concentration of 50 mg/mL. (Control animals
received only saline solution.) On days 3, 7, 10, 12, 14, and
17 the animals were placed in metabolic cages to collect
24-hour urine samples. Rats were euthanized on day 17
and whole blood was collected by cardiac puncture.
Urine-concentrating ability of ACY-treated rats. To
determine whether ACY affects urine-concentrating
ability, rats were deprived of water. On day 8 of treat-
ment, urine samples from 6 treated rats and 4 control
rats were collected in metabolic cages after 24 hours and
48 hours of water deprivation. Total body weight, urine
osmolality, and chemistries were measured.
Analysis of blood and urine samples. The volume
of each 24-hour urine sample was measured gravimet-
rically. Urine samples were centrifuged in aliquots to
remove suspended material and the supernatants were
analyzed. Urinary osmolality was measured by Vapor
Pressure Osmometer (model 5520; Wescor, Logan, UT,
USA). Plasma and urinary levels of sodium and potas-
sium were measured by flame photometry, and urinary
and plasma phosphate by the molybdate method. The
enzymatic colorimetric method (Labtest, Lagoa Santa,
Brazil) was used to quantify levels of glucose and mag-
nesium in urine and levels of calcium and magnesium
in plasma. Urinary pH was also measured (pH meter,
MP225; Mettler Toledo, Greifensee, Switzerland).
RNA isolation and northern hybridization. Based
on the metabolic cage results, we performed a third
series, initiating identical procedures, performing eu-
thanization on day 8. Kidneys were dissected to sep-
arate cortex and medulla. Total cellular RNA was
extracted from the renal cortex and medulla by the
Chomczynski and Sacchi method [8], quantitated spec-
trophotometrically, and stored at −80◦C. Total RNA
samples (20 lg/lane) were fractionated on a 1.2%
agarose-formaldehyde gel and transferred to a nylon
membrane (Hybond-N, Amersham, Arlington Heights,
IL, USA) by capillary transfer using 10X SSC. Mem-
branes were cross-linked by ultraviolet light. Hybridiza-
tion was performed according to Church and Gilbert [9].
Membranes were washed, blotted, exposed to Phospho-
rImager screens (Molecular Dynamics, Sunnyvale, CA,
USA) at room temperature for 24 hours, and scanned
by the PhosphorImager. cDNA fragments labeled 32P
and corresponding to nucleotides of the mRNA-encoding
rat Na-Pi cotransporter (type IIa, Gene Bank acces-
sion no. M76466) and Na-K-2Cl cotransporter (NKCC2,
Gene Bank accession no. U20973) were used as specific
probes. The c-DNA templates were labeled 32P-dCTP
using the random primer technique (Gibco BRL, Life
Technologies, Gaithersburg, MD, USA). To control for
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loading, densitometric measurements were normalized
for the 18S or b-actin signal in each lane. The Na-Pi-IIa
cDNA probe used was a generous gift from Dr. Heini
Murer at the University of Zurich, Switzerland, and the
NKCC2 cDNA probe used was a generous gift from Dr.
Robert Safirstein at the University of Arkansas.
AQP2 and Na cotransporter specific antibodies.
Peptide-derived polyclonal antibodies specific to the
AQP2 water channel, NKCC2, and Na-Pi-IIa (L697)
were kindly supplied by Dr. Mark Knepper (NHLBI,
NIH, Bethesda, MD, USA).
Preparation of membrane fractions. Cortex or
medulla samples were homogenized in ice-cold isola-
tion solution (200 mmol/L mannitol, 80 mmol/L HEPES,
41 mmol/L KOH, pH 7.5) containing protease in-
hibitors (cocktail protease inhibitor, Sigma Chemical Co.,
St. Louis, MO, USA) by using a Teflon pestle glass homog-
enizer (Schmidt and Co, Frankfurt/M, Germany). The
homogenates were centrifuged at low speed (2000g) for
15 minutes at 4◦C to remove nuclei and cell debris. Sub-
sequently, the supernatants were spun at 100,000g for
1 hour at 4◦C (rotor Ti70i, Beckman Coulter, Fuller-
ton, CA, USA) to produce a pellet containing membrane
fractions enriched for both plasma membranes and intra-
cellular vesicles. The pellets were suspended in isolation
solution with protease inhibitors.
Electrophoresis and immunoblotting. Samples of
membrane fractions were run on either 12.5% polyacry-
lamide gels for AQP2, (SE 600 vertical slab gel unit,
Hoefer Scientific Instruments, San Francisco, CA, USA)
or on 10% polyacrylamide minigels for Na-Pi-IIa and
NKCC2. After transfer by electroelution to nitrocellu-
lose membranes (PolyScreen, PVDF Transfer; New Life
Science), blots were blocked with 5% milk and 0.1%
Tween 20 in phosphate-buffered saline (NaCl 8.7g/L,
dibasic phosphate 7.2 mmol/L, and monobasic phos-
phate 2.8 mmol/L) for 1 hour. Blots were then incu-
bated with one of the following: anti-AQP2 antibody
(1:2000), NKCC2 antibody (0.12 lg/mL), or Na-Pi-IIa
antibody (0.54 lg/mL). The labeling was visualized with
horseradish peroxidase-conjugated (HRP-conjugated)
secondary antibody (anti-rabbit immunoglobulin [Ig]G,
diluted 1:2000, Sigma Chemical Co.) by using an en-
hanced chemiluminescence system (ECL, Amersham,
Buckinghamshire, UK). To control for loading, blots
were incubated with either villin antibody (1:1000; Im-
munotech, Beckman Coulter) or actin antibody (1:3000,
Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
labeling was visualized with HRP-conjugated secondary
antibody (anti-mouse IgG, diluted 1:2000 or anti-goat,
diluted 1:5000, Sigma Chemical Co.).
Quantitation of kidney levels of Na transporters and
AQP2. ECL films with bands within the linear range
were scanned using Image Master VDS (Pharmacia
Biotech, Buckinghamshire, UK). For AQP2, both the
29 and the 35 to 50 kD bands (corresponding to nong-
lycosylated and glycosylated species) were quantitated
by densitometric analysis and normalized with densito-
metric villin protein abundance. Quantitative analysis of
the NKCC2 cotransporter antibody (from 146 to 176 kD,
centered at 161 kD) and the Na-Pi-IIa cotransporter an-
tibody (at 85 kD) was also performed by densitometry.
These bands were normalized through evaluation of den-
sitometric actin protein abundance.
Statistical analysis
All quantitative data are expressed as mean ± SEM.
Differences among the means of multiple parameters
were analyzed by one-way analysis of variance (ANOVA)
followed by Student–Newman-Keuls test. Differences
between two parameters were analyzed by either un-
paired t test or by nonparametric methods (Mann-
Whitney test). P values of less than 0.05 were considered
significant.
RESULTS
ACY-treated patients had increased phosphaturia
and urinary volume
As seen in Table 1, ACY-treated patients presented
increased FEP, FENa, and FEK over the course of the
treatment. Increased FEP was accompanied by a signifi-
cant decrease in plasma phosphate. Treatment with ACY
caused a significant increase in urinary volume compared
with pretreatment levels.
ACY treatment was associated with hyperphosphaturia
and hypophosphatemia
ACY-treated rats had significantly increased phos-
phate excretion compared with before the treatment
(Table 2). Consistent with this, ACY-treated rats had
markedly decreased plasma phosphate concentration
(Pre-ACY = 3.77 ± 0.34 mmol/L vs.: 7th day = 1.9 ±
0.31 mmol/L; 17th day = 2.0 ± 0.28 mmol/L, P < 0.005)
(Fig. 1).
ACY causes a specific proximal tubular dysfunction
The proximal effect of ACY appears to be specific in
phosphate reabsorption because glycosuria was not ob-
served. There was no difference between glucose urinary
excretion before or after initiation of the treatment (day
0 vs. day 8: 2.39 ± 0.25 mg/day vs. 2.12 ± 0.35 mg/day).
Serum magnesium and calcium in ACY-treated rats
Rats treated with ACY developed significant hypo-
magnesemia. A decline in serum Mg was observed at
8 days (1.79 ± 0.04 mg/dL vs. 2.0 ± 0.08 mg/dL before
initiation of treatment, P < 0.05) (Fig. 2). There was
an increase in serum calcium after the beginning of the
178 Andrade et al: Acyclovir-induced polyuria and hypophosphatemia
Table 1. Data from patients receiving ACY (15 mg/kg bw/d, IV)
Plasma phosphate Plasma phosphate Urinary volume Urinary volume
pre (mg/dL) during (mg/dL) FEP (%) FENa (%) FEK (%) pre (mL/kg/h) during (mL/kg/h)
4.5 ± 0.3 2.0 ± 0.2a 28.2 ± 4.1 3.0 ± 0.9 24.7 ± 5.3 1.4 ± 0.2 3.9 ± 0.7b
Values are mean ± SEM. Plasma phosphate concentration before and during treatment.
aP < 0.0001 vs. plasma phosphate pretreatment.
bP < 0.005 vs. urinary volume pretreatment.
Table 2. Physiologic data in ACY-treated rats
Day Urinary volume mL/day UPV lmol/day UMgV mg/day UNaV mEq/day UkV mEq/day
Pre-ACY 8.7 ± 1.5a 181.7 ± 39.5a 1.15 ± 0.11b 1.3 ± 0.2c 1.56 ± 0.20b
3rd 47.2 ± 9.4 544.2 ± 148.3 2.46 ± 1.10 3.2 ± 1.0 7.10 ± 2.00
7th 34.5 ± 6.4 937.5 ± 195.5 2.80 ± 0.57 3.5 ± 0.6 7.47 ± 1.60
10th 51.7 ± 14.7 1175.2 ± 230.0 2.63 ± 0.22 3.7 ± 0.8 8.37 ± 1.74
12th 38 ± 12.3 972.75 ± 195.8 ND 4.2 ± 0.6 8.65 ± 0.84
14th 49.2 ± 6.2 1059.2 ± 124.0 2.33 ± 0.20 3.6 ± 0.4 7.35 ± 0.95
17th 32.7 ± 4.8 1058.0 ± 122.1 2.35 ± 0.20 2.8 ± 0.2 5.26 ± 1.36
Urinary volume: urinary phosphate, magnesium, sodium, and potassium excretion were measured days before and after ACY treatment. Values are mean ± SEM.
Days of treatment were compared to previous ACY treatment (ANOVA followed by Student–Newman-Keuls test). ACY, Acyclovir; ND, not determined.
aP < 0.001 vs. the other days.
bP < 0.05 vs. the other days.
cP < 0.01 vs. the other days.
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Fig. 1. Plasma phosphate concentration before and after initiation of
acyclovir (ACY) treatment (N = 8). Concentration decreased signifi-
cantly after initiation of treatment (pre-ACY vs. other days).
treatment. Hypercalcemia was also observed at 8 days
(12.1 ± 0.64 mg/dL vs. 9.6 ± 0.16 mg/dL before initiation
of treatment, P < 0.05) (Fig. 2).
Hypomagnesemia in ACY-treated rats was associated
with hypermagnesuria
Rats treated with ACY developed significantly in-
creased magnesium excretion compared with pretreat-
ment levels (Table 2).
Acy treatment was associated with alterations in renal
water and in sodium and potassium handling
ACY was associated with alterations in renal water and
in sodium and potassium handling. Treated animals had
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Fig. 2. Serum magnesium and calcium levels before and after initiation
of acyclovir (ACY) treatment. Hypomagnesemia and hypercalcemia
developed in ACY-treated animals.
significantly increased urine output compared with prior
before treatment (Table 2).
In parallel, increase in urine output was accompanied
by a significant increase in sodium and potassium excre-
tion. Treated animals had significantly increased sodium
excretion compared with before the treatment (Table 2).
This demonstrates that chronic ACY treatment is as-
sociated with significant natriuresis. Treated animals also
had significantly increased potassium excretion com-
pared with before the treatment (Table 2).
Urinary osmolality in ACY-treated rats was lower
Increased urine output was accompanied by a signif-
icant increase in water intake (data not shown). Con-
sistent with this, ACY-treated rats had markedly lower
urine osmolality compared with before the treatment:
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Fig. 3. Urine osmolality before (pre-acyclovir [ACY]) and after initia-
tion of treatment. ACY-treated rats had markedly lower urine osmolal-
ity: pre-ACY vs. 8th day.
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Fig. 4. Urinary osmolality before and after 24 hours and 48 hours of
water deprivation for control and acyclovir (ACY)-treated rats.
2481 ± 205 mOsm\kg (pre-ACY) versus 651 ± 43
mOsm\kg (18th day), P < 0.0001 (Fig. 3).
ACY induced partial urinary-concentrating defect
To determine whether polydipsic/polyuric ACY-
treated rats could concentrate urine, samples were col-
lected in metabolic cages at 0 hours, 24 hours, and 48 hours
of water deprivation. The ACY-treated rats, as well as the
control animals, remained active after water deprivation.
Body weight decreased only 12% after 24 hours of water
deprivation and remained unchanged after 48 hours. Uri-
nary volume decreased from 52.8 ± 3.7 mL before water
deprivation to 26 ± 1.8 mL after 24 hours of water depri-
vation and down to 14 ± 3.4 mL after 48 hours. As can
be seen in Figure 4, the treated animals were able to con-
centrate the urine, but not as well as the control animals,
suggesting that they have a partial urine-concentrating
defect. Urine osmolality in control versus ACY-treated
animals was 1293 ± 111 versus 365 ± 24.5 before water
deprivation (P < 0.0001); 1691 ± 164 versus 1594 ± 194
after 24 hours’ water deprivation; and 2696 ± 522 versus
1631 ± 83.5 after 48 hours’ water deprivation (P < 0.05)
(Fig. 4).
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Fig. 5. Proximal Na-Pi cotransporter (Na-Pi-IIa) Northern hybridiza-
tion. (A) Densitometric analyses revealing a marked decrease in cortex
Na-Pi-IIa mRNA levels in treated animals. (B) Representative North-
ern blot showing apical Na-Pi-IIa and 18S transcript levels in cortex
from control and treated-rats.
Na-Pi-IIa cotransporter mRNA level expression is
decreased in ACY-treated animals
In renal proximal tubules, transport of Pi through the
proximal apical membrane is largely performed by the
Na-Pi-IIa cotransporter. Northern blot analysis revealed
that ACY treatment was associated with a significant re-
duction of Na-Pi-IIa mRNA level expression on the 8th
day of treatment (control vs. treated animals: 99.6 ± 19.4
vs. 38.7 ± 4.8%, P < 0.02) (Fig. 5).
Na-Pi-IIa cotransporter protein abundance is decreased
in ACY-treated animals
We next examined the expression of Na-Pi-IIa cotrans-
porter protein in ACY-treated rats in order to correlate
the results with Northern studies. Protein was isolated
from rat cortex on the 8th day of treatment. As shown in
Figure 6, Na-Pi-IIa cotransporter protein expression in
treated rats decreased significantly in comparison to con-
trol animals (treated vs. control: 40.3 ± 9.6% vs. 100.0 ±
24.3%, P < 0.03). These results indicate that the abun-
dance of Na-Pi-IIa cotransporter protein in the cortex
correlated with mRNA levels in the cortex on the 8th
day of ACY treatment. Densitometric analyses of Na-Pi-
IIa protein was normalized by densitometric analysis of
actin protein abundance.
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Fig. 6. Semiquantitative immunoblotting of membrane fractions of
kidney cortex. (A) Densitometric analysis revealed a decrease in cortex
Na-Pi abundance in acyclovir (ACY)-treated rats. (B) Immunoblots re-
acted with anti-Na-Pi (anti-Na-Pi-IIa) revealed a band of approximately
85 kD. Densitometric analysis of Na-Pi-IIa protein was normalized by
densitometric analysis of actin protein.
ACY treatment is associated with reduced NKCC2
cotransporter mRNA levels
The apical Na-K-2CL cotransporter is the major trans-
porter for the apical sodium reabsorption by the thick
ascending limb (TAL). Figure 7 shows a representative
Northern blot hybridized with a probe for NKCC2 and
b-actin. The summation of results from all experimental
animals as determined by densitometric analyses of the
Northern blot is shown in Figure 7. By the 8th day of treat-
ment, mRNA expression for NKCC2 was approximately
59% of that found in nontreated animals (treated vs. con-
trol animals: 59.0 ± 14.7% vs. 100.1 ± 11.0%, P < 0.05).
ACY treatment is associated with reduced NKCC2
cotransporter protein levels
To examine whether ACY treatment downregulates
NKCC2 protein abundance, immunoblot analysis was
performed on protein from the entire medulla. As indi-
cated in Figure 8, NKCC2 protein expression significantly
decreased in the medulla on the 8th day of ACY treat-
ment (treated vs. control animals: 52.8 ± 6.5% vs. 100.2 ±
6.1%, P < 0.002). Densitometric analyses of NKCC2 pro-
tein were normalized by densitometric analysis of actin
protein abundance.
Changes in kidney medulla abundance of AQP2 in
response to ACY treatment
Semiquantitative immunoblotting, using membrane
fractions prepared from medullas harvested from con-
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Fig. 7. Apical Na-k-2Cl (NKCC2) cotransporter Northern hybridiza-
tion. (A) Densitometric analyses revealing a marked decrease in
medulla NKCC2 mRNA levels in treated animals. (B) Representative
Northern blot showing apical NKCC2 and b-actin transcript levels in
medullas from control and treated rats.
trol rats and ACY-treated rats (on the 8th day), revealed
that ACY was associated with reduced AQP2 expres-
sion (control vs. treated rats: 99.9 ± 5.2 vs. 72.5 ± 3.5,
P < 0.005). Densitometric analyses of AQP2 protein were
normalized with densitometric villin protein abundance
(Fig. 9).
DISCUSSION
We have demonstrated that the expression of the major
sodium-phosphate cotransporter Na-Pi-IIa was severely
reduced during ACY treatment, and that this was asso-
ciated with phosphaturia and hypophosphatemia. More-
over, the expression of the major thick ascending limb
sodium transporter (NKCC2) was decreased, suggesting
that altered sodium transporter expression may be sig-
nificantly involved in the development of ACY-induced
polyuria. Additionally, we have demonstrated that the
expression of collecting duct water channel AQP2 was
partially reduced after ACY treatment, and that this was
associated with an impairment of the ability to concen-
trate urine.
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Fig. 8. Semiquantitative immunoblotting of membrane fractions of
kidney medulla. (A) Densitometric analysis revealed a decrease in
medulla NKCC2 (Na-K-2Cl) abundance in ACY-treated rats. (B) Im-
munoblots reacted with anti-NKCC2 revealed a band of approximately
146 to 176 kD (centered at 161 kD). Densitometric analysis of NKCC2
protein was normalized by densitometric analysis of actin protein.
Decreased expression of Na-Pi-IIa in
ACY-treated rats
Our results demonstrated that Na-Pi-IIa expression
in the proximal tubule was significantly decreased in
rats receiving ACY treatment. Na-Pi-IIa is expressed
in the proximal tubule and contributes to renal proxi-
mal tubular phosphate reabsorption [10]. ACY treatment
raises serum calcium and lowers serum phosphate con-
centrations, and increases urinary phosphate excretion.
We have also demonstrated that the proximal effect of
ACY appears to be specific in phosphate reabsorption
because glycosuria was not observed. The mechanism of
the downregulation of Na-Pi cotransporter by ACY still
cannot be explained. ACY is the leading therapy for her-
pes simplex virus, an important human pathogen. ACY is
a nucleoside analog that is a prototype of many other anti-
herpes virus and anti-HIV drugs [11]. The major route of
ACY elimination is excretion in the urine [3]. The cel-
lular uptake and initial phosphorylation are facilitated
by virus thymidine kinase. The affinity of ACY for HSV
thymidine kinase is about 200-fold greater than for the
mammalian enzymes [12]. Uninfected cells convert very
little or no drug to the phosphorylated derivates. Thus,
ACY is selectively activated in cells infected with her-
pes viruses that code for appropriated thymidine kinase.
ACY renal clearance exceeded glomerular filtration, and
tubular secretion of ACY is probably a major route of
drug clearance [13]. Therefore, it can reach very high
concentration in proximal tubular cells. ACY acts as a
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Fig. 9. Semiquantitative immunoblotting of membrane fractions of
kidney medulla. (A) Densitometric analysis revealed a decrease in
medulla aquaporin 2 (AQP2) abundance in acyclovir (ACY)-treated
rats. (B) Immunoblots reacted with anti-AQP2 revealed 29- and 35
to 50-kD AQP2 bands, representing nonglycosylated and glycosylated
forms of AQP2, respectively. Densitometric analysis of AQP2 protein
was normalized by densitometric analysis of villin protein.
chain terminator due to its lack of 3′-hydroxyl group. By
a mechanism termed suicide inactivation, the terminated
DNA template containing ACY binds the enzyme and
leads to irreversible inactivation of the DNA polymerase
[14]. Because tubular secretion is the major route of ACY
clearance, high levels of the drug in the proximal tubule
may account for this tubular cellular dysfunction.
Increased natriuresis and kaliuresis in
ACY-treated rats
The Na-K-2Cl cotransporter NKCC2, which is lo-
calized at the apical plasma membrane domains of
medullary and cortical TAL segments, mediates the api-
cal NaCl transport in these water-impermeable segments
[15, 16]. We have demonstrated that a decrease in the
expression of this cotransporter leads to an increase in
sodium and potassium excretion. This is consistent with
previous observations by Campos et al [6] in which ACY-
treated animals became polyuric and presented an in-
crease in blood urea nitrogen and fractional excretion
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of sodium and potassium. Moreover, they have also
suggested, in free-water clearance and free-water reab-
sorption experiments, an effect of ACY on the prox-
imal tubule and thick ascending limb consistent with
our data. The cause of the decrease in NKCC2 expres-
sion is not ascertainable from the present results. It is
also possible that the decrease in transporter expression
in this model is similar to the Na-Pi-IIa cotrans-
porter inhibition. ACY can reach very high concentra-
tion in the kidneys. Another possibility is that which
Wang et al [17] have shown that hypercalcemia in rats
can cause marked reduction of NKCC2 abundance in
kidneys.
Treated animals demonstrated a significant decrease
in plasma magnesium and an increase in urinary magne-
sium excretion. Magnesium moves passively across the
epithelium or between the cells (paracellular pathway),
driven by a transepithelial-positive voltage in the thick
ascending limb [18]. A positive luminal voltage has been
postulated to be important in the passive reabsorption
of cations such as magnesium [19]. Factors that influence
NaCl transport, such as the decrease of NKCC2 expres-
sion, are expected to affect the transepithelial voltage and
thus the passive transport of magnesium [20].
Polyuria and urinary-concentrating capacity in
ACY-treated animals
It has been demonstrated that ACY causes crystal-
induced acute renal failure [4, 5, 21, 22, 23]. Some con-
cerns about this finding must be addressed.
In animal studies, crystals were observed in the col-
lecting tubules of the papilla, predominantly at its tip.
Crystallization was slight at 10 minutes, but by 30 min-
utes, most of the collecting tubules in the papilla were
packed with refractile material. By 60 minutes, crystals
decreased in number, and by 120 minutes, most of the
animals showed no intratubular crystals [24]. The animal
studies suggest that the increases in blood urea/creatinine
seen in some patients treated with ACY are caused by a
transient crystal nephropathy, which occurs only when
the concentration of ACY in the collecting duct of the
tubule exceeds the drug’s solubility. This probably occurs
for short periods when the ACY plasma concentrations
are very high, such as immediately after a bolus injec-
tion. Peak plasma levels are reduced when ACY is given
by slow intravenous infusion over 1 hour [25]. Since this
dosing regimen was instituted, fewer cases of renal im-
pairment by crystal obstruction have been reported. All
reported cases were in patients suffering from dehydra-
tion. In fact, in a euvolemic condition, accumulation of
crystals in the renal tubule can be prevented and no ob-
structive event will be observed. The renal dysfunction re-
ported in some cases of patients treated with large doses
of ACY was usually reversible and could be avoided by
infusing ACY gradually and in association with sufficient
hydration.
Santos et al [26] have shown that ACY induced a nono-
liguric acute renal failure and no tubular obstruction was
detected in the animal’s kidney by light microscopy. They
also observed that ACY promoted ARF, with a reduction
in GFR, marked vasoconstriction, and maintenance (or
elevation) of the rate of urine production. It was the first
demonstration of ACY effects on renal microcirculation
in the absence of crystalluria.
In a study of brush border membrane vesicles, Mon-
teiro et al [7] have demonstrated decreased Pi reabsorp-
tion in ACY-treated animals. They also demonstrated
polyuria and decreased urinary osmolality.
A partial defect in urinary concentrating capacity has
also been observed in our data. In the normal state, urine
is concentrated as a result of the combined functions of
the loop of Henle and the collecting duct. The loop of
Henle generates a high osmolality in the renal medulla by
driving the countercurrent multiplication process [27, 28].
The collecting duct, when vasopressin is present, permits
osmotic equilibration between the urine and the hyper-
tonic medullary interstitium [29, 30]. The development of
high osmolality in the renal medulla is dependent on net
NaCl absorption by the thick ascending limb. Here we
demonstrated marked decreases in the expression levels
of NKCC2 thick ascending limb Na transporter. This sup-
pressed expression results in decreased active NaCl ab-
sorption by TAL and is therefore predictive of decreased
countercurrent multiplication of NaCl in treated animals
[31]. We have also shown a 30% decrease in AQP2 expres-
sion. Such a decrease in collecting duct water channel ex-
pression might be due in part to decreased generation of
medullary interstitial hypertonicity, induced by NKCC2
cotransporter [32] or by a direct effect of ACY on the
collecting duct cells. Confirming our findings regarding
AQP2 expression, Campos et al [6] have shown reduced
reabsorption of solute-free water in ACY-treated rats
when compared to that of normal rats. We have demon-
strated that the treated animals were able to partially con-
centrate urine, but not as well as the control animals. This
partial urinary concentrating ability can be explained by
a 70% abundance of collecting duct water channel AQP2
[33–36]. Moreover, because hypercalcemia is known to
be associated with downregulation of AQP2, hypercal-
cemia may also contribute to ACY-induced polyuria [17,
37, 38].
In our results, we showed a 6-fold increase in urinary
phosphate excretion accompanied by a modest decrease
in serum phosphate concentration in ACY-treated ani-
mals. In addition, ACY-treated rats developed hypercal-
cemia. Phosphate is the major anionic component of the
mineralized bone matrix. Based on these findings, we hy-
pothesized that there is a net phosphate efflux, probably
from bone.
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CONCLUSION
Downregulation of Na-Pi-IIa appears to play a crucial
role in the downregulation of ACY-induced hypophos-
phaturia. The accompanying polyuria and urinary-
concentrating defect can in part be explained by the
downregulation of NKCC2 and AQP2.
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